Valneva has partnered with LimmaTech Biologics to acquire exclusive rights to develop and market Shigella4V, a vaccine candidate against shigellosis. The agreement includes an upfront payment...
Valneva will soon be able to sell its Covid-19 vaccine candidate. On the European side, Valneva has broken off negotiations with the European Commission, preferring bilateral...